Fluid intake must be limited to a min from 1 hr before until 8 hr after administration. Increased risk of hyponatremia in elderly patients w/ serum Na levels in the lower range of normal; females at a 50 mcg dose levels. Discontinue use if serum Na levels falls below the lower limit of normal range. Patients w/ conditions characterized by fluid &/or electrolyte imbalance (eg, systemic infections, fever & gastroenteritis). Concomitant w/ drugs known to induce SIADH eg, TCAs, SSRIs, chlorpromazine, diuretics & carbamazepine & some antidiuretics of the sulfonylurea group, particularly chlorpropamide & NSAIDs. Monitor Na in patients taking thiazide or loop diuretics for HTN or other medical conditions not associated w/ fluid overload. Severe bladder dysfunction & outlet obstruction should be considered before starting treatment. Cystic fibrosis, CHD, HTN, chronic renal disease & pre-eclampsia. Consider diagnosis of nephrogenic diabetes insipidus if there is no reduction in night‑time urine output after commencement of desmopressin. Patients taking lithium in case of masking of early-stage lithium-induced nephrogenic diabetes insipidus. Not recommended in patients suspected of having lithium-induced nephrogenic diabetes insipidus. Pregnancy & lactation. Childn. Elderly ≥65 yr.
Sign Out
